Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay

Abstract Background Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept) is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of this study was to evaluate the in-vitro effects of CTLA4-Ig...

Full description

Bibliographic Details
Main Authors: Maurizio Cutolo, Stefano Soldano, Paola Montagna, Amelia Chiara Trombetta, Paola Contini, Barbara Ruaro, Alberto Sulli, Stefano Scabini, Emanuela Stratta, Sabrina Paolino, Carmen Pizzorni, Vanessa Smith, Renata Brizzolara
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Arthritis Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13075-018-1652-6